Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P20226 (
TATA-binding protein
)
1,297
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
PTEN
, a tumor suppressor whose function is frequently lost in human cancers, possesses a lipid phosphatase activity that represses phosphatidylinositol 3-kinase (PI3K) signaling, controlling cell growth, proliferation, and survival. The potential for
PTEN
to regulate the synthesis of RNA polymerase (Pol) III transcription products, including tRNAs and 5S rRNAs, was evaluated. The expression of
PTEN
in
PTEN
-deficient cells repressed RNA Pol III transcription, whereas decreased
PTEN
expression enhanced transcription. Transcription repression by
PTEN
was uncoupled from
PTEN
-mediated effects on the cell cycle and was independent of p53.
PTEN
acts through its lipid phosphatase activity, inhibiting the PI3K/Akt/mTOR/S6K pathway to decrease transcription.
PTEN
, through the inactivation of mTOR, targets the TFIIIB complex, disrupting the association between
TATA-binding protein
and Brf1. Kinetic analysis revealed that
PTEN
initially induces a decrease in the serine phosphorylation of Brf1, leading to a selective reduction in the occupancy of all TFIIIB subunits on tRNA(Leu) genes, whereas prolonged
PTEN
expression results in the enhanced serine phosphorylation of Bdp1. Together, these results demonstrate a new class of genes regulated by
PTEN
through its ability to repress the activation of PI3K/Akt/mTOR/S6K signaling.
...
PMID:PTEN represses RNA polymerase III-dependent transcription by targeting the TFIIIB complex. 1839 Oct 23
MAF1 was discovered as a master repressor of Pol III-dependent transcription in response to diverse extracellular signals, including growth factor, nutrient and stress. It is regulated through posttranslational mechanisms such as phosphorylation. A prominent upstream regulator of MAF1 is the mechanistic target of rapamycin (mTOR) pathway. mTOR kinase directly phosphorylates MAF1, controlling its localization and transcriptional activity. In mammals, MAF1 has also been shown to regulate Pol I- and Pol II-dependent transcription. Interestingly, MAF1 modulates Pol II activity both as a repressor and activator, depending on specific target genes, to impact on cellular growth and metabolism. While MAF1 represses genes such as
TATA-binding protein
(
TBP
) and fatty acid synthase (FASN), it activates the expression of
PTEN
, a major tumor suppressor and an inhibitor of the mTOR signaling. Increasing evidence indicates that MAF1 plays an important role in different aspects of normal physiology, lifespan and oncogenesis. Here we will review the current knowledge on MAF1 in growth, metabolism, aging and cancer. This article is part of a Special Issue entitled: SI: Regulation of tRNA synthesis and modification in physiological conditions and disease edited by Dr. Boguta Magdalena.
...
PMID:Beyond regulation of pol III: Role of MAF1 in growth, metabolism, aging and cancer. 2940 95